Peijia Medical's (HKG:9996) attributable loss narrowed to 226.6 million yuan in 2024 from 392.5 million yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Loss per share at the medical device manufacturer narrowed to 0.34 yuan from 0.58 yuan in the previous year.
Revenue grew 40% to 615.5 million yuan from 441.1 million yuan a year earlier.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。